RAPT Therapeutics (RAPT) Common Equity (2020 - 2024)
Historic Common Equity for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to $95.5 million.
- Therapeutics' Common Equity fell 4473.03% to $95.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $95.5 million, marking a year-over-year decrease of 4473.03%. This contributed to the annual value of $147.0 million for FY2023, which is 4002.63% down from last year.
- According to the latest figures from Q3 2024, Therapeutics' Common Equity is $95.5 million, which was down 4473.03% from $109.2 million recorded in Q2 2024.
- Therapeutics' 5-year Common Equity high stood at $245.2 million for Q4 2022, and its period low was $91.6 million during Q1 2021.
- For the 5-year period, Therapeutics' Common Equity averaged around $160.3 million, with its median value being $167.8 million (2022).
- As far as peak fluctuations go, Therapeutics' Common Equity surged by 8344.25% in 2021, and later tumbled by 4530.17% in 2024.
- Over the past 5 years, Therapeutics' Common Equity (Quarter) stood at $104.2 million in 2020, then surged by 78.9% to $186.4 million in 2021, then surged by 31.54% to $245.2 million in 2022, then crashed by 40.03% to $147.0 million in 2023, then plummeted by 35.05% to $95.5 million in 2024.
- Its Common Equity was $95.5 million in Q3 2024, compared to $109.2 million in Q2 2024 and $130.8 million in Q1 2024.